Patents by Inventor Randy S. Longman

Randy S. Longman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
    Patent number: 10160805
    Abstract: Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: December 25, 2018
    Assignees: New York University, Cornell University
    Inventors: Randy S. Longman, Gretchen E. Diehl, Dan R. Littman
  • PREVOTELLA COPRI AND ENHANCED SUSCEPTIBILITY TO ARTHRITIS
    Publication number: 20160186261
    Abstract: Methods, reagents and compositions thereof for predicting risk for NORA onset in susceptible individuals, diagnosing NORA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of at least one of SEQ ID NOs: 1-19 and/or at least one of a KO presented in either of Tables S4 or S5 serves as a biomarker for the above indications.
    Type: Application
    Filed: November 4, 2014
    Publication date: June 30, 2016
    Inventors: Jose U. Scher, Andrew Sczesnak, Randy S. Longman, Nicola Segata, Carles Ubeda, Eric G. Pamer, Steven B. Abramson, Curtis Huttenhower, Dan R. Littman, Hannah Fehlner-Peach
  • TYPE 3 INNATE LYMPHOID CELL INDUCED GASTROINTESTINAL TRACT MUCOSAL HEALING
    Publication number: 20160009802
    Abstract: Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.
    Type: Application
    Filed: July 13, 2015
    Publication date: January 14, 2016
    Inventors: Randy S. Longman, Gretchen E. Diehl, Dan R. Littman